Clinical Trial: Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06961500) titled 'Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A' on April 29.

Brief Summary: This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-naive follicular lymphoma (Grade 3A) patients.

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: Follicular Lymphoma Grade 3A

Intervention: DRUG: Obinutuzumab

1000mg i.v., administered on Day 1/8/15 (D1/8/15) of Cycle 1 (C1), and D1 of C2-6

DRUG: CHOP

a) Cyclophosphamide: 750 mg/m2 i.v. drip, administe...